600276 Jiangsu Hengrui Pharmaceuticals Co.,Ltd.
Trading 10-08 10:05:35
46.99
-0.21
-0.44%
High47.58Low46.24Vol32.91M
Open47.20D1 Closing47.20Amplitude2.84%
Mkt Cap311.87BTradable Cap299.75BTotal Shares6.64B
T/O1.54BT/O Rate0.52%Tradable Shares6.38B
P/B4.86ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BlackRock's Long Position in H-Shares of Jiangsu Hengrui Increases to 6.99% on Sept 30 from 5.96% - HKEX
THOMSON REUTERS  ·  10-05 17:31
BlackRock's Long Position in H-Shares of Jiangsu Hengrui Increases to 6.99% on Sept 30 from 5.96% - HKEX
UBS Group Ag's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Decreases to 4.59% on Sept 25 from 5.17% - HKEX
THOMSON REUTERS  ·  10-02
UBS Group Ag's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Decreases to 4.59% on Sept 25 from 5.17% - HKEX
Major Drugmakers Turn to China for Licensing Deals
Reuters  ·  10-02
Major Drugmakers Turn to China for Licensing Deals
Major Drugmakers Turn to China for Licensing Deals
Reuters  ·  09-30
Major Drugmakers Turn to China for Licensing Deals
Daiwa: Hengrui Pharma (01276) Reaches Licensing Deal with Novo Nordisk for HRS-1596; Total Transaction Value and Upfront Payment Both Attractive
Stock News  ·  09-30
Daiwa: Hengrui Pharma (01276) Reaches Licensing Deal with Novo Nordisk for HRS-1596; Total Transaction Value and Upfront Payment Both Attractive
Morgan Stanley Maintains Overweight Rating on Hengrui Pharma (01276) with HK$82 Target Price
Stock News  ·  09-30
Morgan Stanley Maintains Overweight Rating on Hengrui Pharma (01276) with HK$82 Target Price
Hong Kong Stock Connect Innovative Drug Sector Defies Market Downturn as Top Pharmaceutical Firm Enters with US$2 Billion, Akeso Surges 15.54%, Hengrui Pharma Secures US$2.6 Billion BD Deal
Deep News  ·  09-29
Hong Kong Stock Connect Innovative Drug Sector Defies Market Downturn as Top Pharmaceutical Firm Enters with US$2 Billion, Akeso Surges 15.54%, Hengrui Pharma Secures US$2.6 Billion BD Deal
Novo Nordisk Strikes Second Licensing Deal Since Frosty Capital-Markets Day
Dow Jones  ·  09-29
Novo Nordisk Strikes Second Licensing Deal Since Frosty Capital-Markets Day
Hengrui Pharma Licenses Oral GLP-1/GIP Weight-Loss Drug to Novo Nordisk in Deal Worth Up to $2.6 Billion
Deep News  ·  09-29
Hengrui Pharma Licenses Oral GLP-1/GIP Weight-Loss Drug to Novo Nordisk in Deal Worth Up to $2.6 Billion
Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral Glp-1/Gip Dual Receptor Agonist Hrs-1596
THOMSON REUTERS  ·  09-29
Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral Glp-1/Gip Dual Receptor Agonist Hrs-1596
China's Hengrui Inks up to $2.6 Billion Deal with Novo Nordisk for Obesity Drug
Reuters  ·  09-29
China's Hengrui Inks up to $2.6 Billion Deal with Novo Nordisk for Obesity Drug
Hengrui Pharma and Novo Nordisk Sign Licensing Agreement for HRS-1596 Project
Stock News  ·  09-29
Hengrui Pharma and Novo Nordisk Sign Licensing Agreement for HRS-1596 Project
Hengrui Pharma Licenses GLP-1/GIP Drug HRS-1596 to Novo Nordisk in Deal Worth up to USD 2.6 Billion
Reuters  ·  09-29
Hengrui Pharma Licenses GLP-1/GIP Drug HRS-1596 to Novo Nordisk in Deal Worth up to USD 2.6 Billion
Jiangsu Hengrui Pharmaceuticals - Entering into License Agreement for Hrs-1596 with Novo Nordisk a/S
THOMSON REUTERS  ·  09-29
Jiangsu Hengrui Pharmaceuticals - Entering into License Agreement for Hrs-1596 with Novo Nordisk a/S
Jiangsu Hengrui Pharmaceuticals - Potential Total Value of Agreement up to $2.6 Bln Contingent on Achievement of Applicable Development, Others
THOMSON REUTERS  ·  09-29
Jiangsu Hengrui Pharmaceuticals - Potential Total Value of Agreement up to $2.6 Bln Contingent on Achievement of Applicable Development, Others
Jiangsu Hengrui Pharmaceuticals - Dedal Includes $300 Mln Upfront Payment
THOMSON REUTERS  ·  09-29
Jiangsu Hengrui Pharmaceuticals - Dedal Includes $300 Mln Upfront Payment
Jiangsu Hengrui Pharmaceuticals - Co Also Eligible to Receive Royalties Based on Net Sales of Hrs-1596 Within Licensed Territory
THOMSON REUTERS  ·  09-29
Jiangsu Hengrui Pharmaceuticals - Co Also Eligible to Receive Royalties Based on Net Sales of Hrs-1596 Within Licensed Territory
Blackrock's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 7.32%, Says HKEX
Reuters  ·  09-25
Blackrock's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 7.32%, Says HKEX
UBS Group Ag's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 5.23% on Sept 21 from 4.43% - HKEX
THOMSON REUTERS  ·  09-25
UBS Group Ag's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 5.23% on Sept 21 from 4.43% - HKEX
HENGRUI PHARMA Spends RMB 11.37 Million Buying Back 250,000 A-Shares on September 23
Stock News  ·  09-23
HENGRUI PHARMA Spends RMB 11.37 Million Buying Back 250,000 A-Shares on September 23

Introduction

Company Name.
江苏恒瑞医药股份有限公司
Industry:
医药制造业
Listing Date:
2000-10-18
Main Business:
　　江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是注射用卡瑞利珠单抗、羟乙磺酸达尔西利片、瑞维鲁胺片、海曲泊帕乙醇胺片、脯氨酸恒格列净片、碘佛醇注射液。
Issue price:
11.98